Overcoming Acquired Drug Resistance to Cancer Therapies Through Targeted STAT3 Inhibition

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 11

PMID 36902166

Authors

Sunanda Singh

Hector J Gomez

Shreya Thakkar

Samara P Singh

Ashutosh S Parihar

Affiliations

Soon will be listed here.

Abstract

Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose their efficacy due to the development of acquired drug resistance (ADR). In this review, we evaluate the scientific and medical literature that elucidate STAT3-mediated mechanisms of resistance to cancer therapeutics. Herein, we have found that at least 24 different anti-neoplastic agents-standard toxic chemotherapeutic agents, targeted kinase inhibitors, anti-hormonal agents, and monoclonal antibodies-that utilize the STAT3 signaling pathway as one mechanism of developing therapeutic resistance. Targeting STAT3, in combination with existing anti-neoplastic agents, may prove to be a successful therapeutic strategy to either prevent or even overcome ADR to standard and novel cancer therapies.

Citing Articles

Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).

Jin Z, Li Y, Yi H, Wang M, Wang C, Du S Int J Oncol. 2025; 66(3).

PMID: 39950314 PMC: 11844340. DOI: 10.3892/ijo.2025.5728.

Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway.

Luo X, Duan Y, He J, Huang C, Liu J, Liu Y Front Oncol. 2025; 15:1429018.

PMID: 39944829 PMC: 11813777. DOI: 10.3389/fonc.2025.1429018.

A New IL-6-Inducing Mechanism in Cancer with New Therapeutic Possibilities.

Hakansson L, Duner P, Brostromer E, Gustavsson B, Wettergren Y, Ghafouri B Cancers (Basel). 2024; 16(21).

PMID: 39518029 PMC: 11545478. DOI: 10.3390/cancers16213588.

A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer.

Rajaram J, Mende L, Kuthati Y Pharmaceutics. 2024; 16(9).

PMID: 39339158 PMC: 11434998. DOI: 10.3390/pharmaceutics16091120.

STAT3 Pathways Contribute to β-HCH Interference with Anticancer Tyrosine Kinase Inhibitors.

Fiorini S, Rubini E, Perugini M, Altieri F, Chichiarelli S, Meschiari G Int J Mol Sci. 2024; 25(11).

PMID: 38892372 PMC: 11173063. DOI: 10.3390/ijms25116181.

References

Jin P, Liu Y, Wang R . STAT3 regulated promotes ovarian cancer proliferation and cisplatin resistance. Biosci Rep. 2018; 38(4). PMC: 6131203. DOI: 10.1042/BSR20180547. View

Gu H, Park S, Choi S, Lee J, Kim Y, Han C . Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol. 2015; 21(1):49-59. PMC: 4379197. DOI: 10.3350/cmh.2015.21.1.49. View

Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. PMC: 2634900. DOI: 10.1073/pnas.0810958105. View

Mohammadian J, Mahmoudi S, Pourmohammad P, Pirouzpanah M, Salehnia F, Maroufi N . Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2020; 393(12):2315-2323. DOI: 10.1007/s00210-020-01942-x. View

Harada D, Takigawa N, Kiura K . The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2014; 6(2):708-22. PMC: 4074799. DOI: 10.3390/cancers6020708. View

Berman H, Henrick K, Nakamura H . Announcing the worldwide Protein Data Bank. Nat Struct Biol. 2003; 10(12):980. DOI: 10.1038/nsb1203-980. View

Rebe C, Ghiringhelli F . STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers (Basel). 2019; 11(9). PMC: 6770459. DOI: 10.3390/cancers11091280. View

Wang L, Zhang Z, Wang L, Wei H, Zhang T, Zhang L . TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways. Cell Death Dis. 2022; 13(5):472. PMC: 9120066. DOI: 10.1038/s41419-022-04890-x. View

Gong J, Munoz A, Pingali S, Payton-Stewart F, Chan D, Freeman J . Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells. Mol Carcinog. 2016; 56(2):402-411. PMC: 5800424. DOI: 10.1002/mc.22503. View

10.

Hatiboglu M, Kong L, Wei J, Wang Y, McEnery K, Fuller G . The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2011; 131(1):8-17. PMC: 3319790. DOI: 10.1002/ijc.26307. View

11.

Adeshakin F, Adeshakin A, Liu Z, Lu X, Cheng J, Zhang P . Upregulation of V-ATPase by STAT3 Activation Promotes Anoikis Resistance and Tumor Metastasis. J Cancer. 2021; 12(16):4819-4829. PMC: 8247373. DOI: 10.7150/jca.58670. View

12.

Giacinti S, Poti G, Roberto M, Macrini S, Bassanelli M, Di Pietro F . Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. Anticancer Res. 2018; 38(11):6029-6039. DOI: 10.21873/anticanres.12953. View

13.

Ouedraogo Z, Biau J, Kemeny J, Morel L, Verrelle P, Chautard E . Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Mol Neurobiol. 2016; 54(8):5780-5797. DOI: 10.1007/s12035-016-0103-0. View

14.

Nagathihalli N, Castellanos J, VanSaun M, Dai X, Ambrose M, Guo Q . Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget. 2016; 7(40):65982-65992. PMC: 5323208. DOI: 10.18632/oncotarget.11786. View

15.

Fofaria N, Srivastava S . STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis. 2014; 36(1):142-50. PMC: 4291051. DOI: 10.1093/carcin/bgu233. View

16.

Moon S, Lee H, Kim S, Hong J, Chun S, Lee H . Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. BMC Cancer. 2021; 21(1):931. PMC: 8371881. DOI: 10.1186/s12885-021-08641-7. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Huyen N, Prachayasittikul V, Chan-On W . Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation. J Hepatobiliary Pancreat Sci. 2016; 23(7):397-405. DOI: 10.1002/jhbp.354. View

19.

Byun W, Bae E, Cui J, Park H, Oh D, Lee S . Antitumor Activity of Pulvomycin via Targeting Activated-STAT3 Signaling in Docetaxel-Resistant Triple-Negative Breast Cancer Cells. Biomedicines. 2021; 9(4). PMC: 8074004. DOI: 10.3390/biomedicines9040436. View

20.

You L, Wang Z, Li H, Shou J, Jing Z, Xie J . The role of STAT3 in autophagy. Autophagy. 2015; 11(5):729-39. PMC: 4509450. DOI: 10.1080/15548627.2015.1017192. View